Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 7.9%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price was down 7.9% on Wednesday . The company traded as low as $0.50 and last traded at $0.51. Approximately 187,369 shares changed hands during trading, a decline of 87% from the average daily volume of 1,417,318 shares. The stock had previously closed at $0.55.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday, March 27th.

Kiora Pharmaceuticals Trading Down 3.9 %

The business has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.59.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Boothbay Fund Management LLC acquired a new stake in shares of Kiora Pharmaceuticals during the 4th quarter worth $40,000. Dimensional Fund Advisors LP acquired a new stake in shares of Kiora Pharmaceuticals during the 1st quarter worth $41,000. Acadian Asset Management LLC acquired a new stake in shares of Kiora Pharmaceuticals during the 1st quarter worth $70,000. Citadel Advisors LLC acquired a new stake in shares of Kiora Pharmaceuticals during the 4th quarter worth $49,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Kiora Pharmaceuticals during the 1st quarter worth $58,000. Hedge funds and other institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.